16% of patients with nr-axSpA progressed to r-axSpA within 5 years. Male sex, fulfillment of the imaging arm of the ASAS criteria, and good response to nonsteroidal anti-inflammatory drugs were predictors of radiographic progression https://t.co/eargDLHUZ2 https://t.co/xG52uMmYK8

Study of 235 newly Dx #RA patients (157 females) found that 11 pts (5%) had carpal tunnel syndrom (CTS) at the time of initial RA diagnosis. Such pts were more likey to be older, female, CCP negative and have a longer Sx duration. https://t.co/0CfF0lKBgk https://t.co/tx9CvQ4TWX

No evidence of harm starting urate lowering Tx (ULT) during #gout attack. Metanalysis 6 RCTs (445 pts) w/ gout attacks given ULT vs PBO or delayed ULT. No differences in pain, time to resolve gout flare or risk of recurrent gout flare in 30d (RR 1.06) https://t.co/xUX2U6MmGP https://t.co/2bV0g2FOSK

Meta-analysis of 35 RCTs (>20K pts) with inflammatory skin disorders shows that w/ short-term (<5 mos) use JAK inhibitors do not significantly increase risk of all-cause mortality (OR, 0.83; 0.44-1.57), MACE, or VTE (OR, 0.52; 0.26-1.04). https://t.co/zBlcZ02QqQ https://t.co/cXjswVS9lF

Microbiome study of 16 SLE pts (44 fecal samples) shows that blooms of Ruminococcus gnavus pathobiont was assoc w/ lupus flares and may be the drivers of clinical of relapsing lupus disease https://t.co/OXA4L6kG4p https://t.co/zXX7ZfWik1

2019 NHIS chronic pain study shows signif disparity in nonpharmacologic & integrative medicine (IHM) use by populations. More IHM with city living, higher income & education, widespread pains. Less IHM w/ elderly, males, Blacks, opioid use, depression https://t.co/uoOyQBXTmy https://t.co/yTTVc5zljG

Join us this weekend! More than 25 sessions on topics ranging from spondyloarthritis, PsA, vasculitis and lupus to JAK inhibitors, RA, artificial intelligence and myositis. CME and MOC offered. Learn more about our program and registration options today! https://t.co/6uWDDIUnvA https://t.co/aWk4IKZYC4

ACR Applauds Prior Authorization Rule The ACR applauds the CMS for finalizing its Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations rule recently. https://t.co/ZVPl2bUT3g https://t.co/ynynH0A8XN

Severe Hypocalcemia Risk w/Denosumab and CKD Patients On 1/19 the FDA issued a Drug Safety Communication about the risk of severe hypocalcemia in CKD patients taking denosumab for osteoporosis. https://t.co/VPpIZBZQkm https://t.co/yxFYn1ob5A

What do you know about monogenic and polygenic autoinflammatory diseases? Join Drs Liebowitz and Mehta as they review the challenges of these conditions. https://t.co/z0mTZEwFkP https://t.co/LAxl2eFZKR

QD Clinic - RA, SSZ, & MI RA with a myocardial inflarction - which DMARD? https://t.co/9o83xedJ3j https://t.co/P5jmZAZ9rt

Join us this weekend! More than 25 sessions on topics ranging from spondyloarthritis, PsA, vasculitis and lupus to JAK inhibitors, RA, artificial intelligence and myositis. CME and MOC offered. Learn more about our program and registration options today! https://t.co/Iac2T2Kohs https://t.co/zu1WJLOcmh